Prof. Chunmei Bai 白春梅
Chief Physician, Professor
Department of Medical Oncology, Peking Union Medical College Hospital, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Personalized and comprehensive treatment for digestive system tumors and neuroendocrine tumors.
Dr. Bai holds an MD from Beijing Medical University (1989) and a PhD in Internal Medicine from Peking Union Medical College (1999). Dr. Bai trained at the University of North Carolina School of Medicine in 2000 and formerly served as Director of the Department of Medical Oncology at Peking Union Medical College Hospital. Research focuses on tumor diagnosis and treatment, particularly molecular markers. Dr. Bai has participated in national clinical studies on advanced gastrointestinal tumors and anticancer drug trials.
Professional roles
- Executive Committee Member, China Anti-Cancer Association
- Executive Committee Member, Geriatric Oncology Society
- Member, CSCO Clinical Chemotherapy Professional Committee
- Member, CSCO Gastric Cancer Professional Committee
Name order: in Chinese the family name comes first (Bai Chunmei). Papers usually list the name as Chunmei Bai or Bai C.
Selected publications
160 papers on PubMed matched by name and affiliation; 30 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Immunol, 2026 (senior author): Research advances in Janus kinase inhibitors for immune checkpoint inhibitors-related myocarditis. PubMed 42979192
- Pancreatology, 2026 (senior author): Genomic characterization and prognosis of pancreatic adenosquamous carcinoma. PubMed 41461591
- Front Immunol, 2025 (senior author): Single-center experience with immune checkpoint inhibitor-related ureteritis and cystitis. PubMed 41641271
- Front Immunol, 2025 (senior author): Case report of immune checkpoint inhibitor induced cholestatic hepatitis, acute renal injury and asymptomatic pancreatic enzyme elevation simultaneously. PubMed 41346594
- Eur J Cancer, 2025 (first author): Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial. PubMed 41005213
- Ther Adv Med Oncol, 2025 (senior author): S-1 plus oxaliplatin versus modified FOLFIRINOX for advanced pancreatic adenocarcinoma after gemcitabine plus nab-paclitaxel failure. PubMed 41018042
- Front Immunol, 2024 (senior author): Perioperative tislelizumab with four cycles of neoadjuvant chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: a phase 2 study. PubMed 39687611
- J Cancer Surviv, 2024 (senior author): The prognostic role of WeChat-based instant doctor-patient communication in patients with advanced pancreatic cancer. PubMed 37460857
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion